Virtu Financial’s Scinai Immunotherapeutics SCNI Stock Holding History

Virtu Financial’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,409	Closed	-$11K	–	2223
2025 Q4	$11K	Buy	+15,409	New	+$17.6K	﹤0.01%	1502
2023 Q2	–	Sell	-1,051	Closed	-$23K	–	1972
2023 Q1	$23K	Buy	+1,051	New	+$25.9K	﹤0.01%	1224
2021 Q4	–	Sell	-223	Closed	-$49K	–	2123
2021 Q3	$49K	Buy	+223	New	+$57.2K	﹤0.01%	1278
2021 Q2	–	Sell	-183	Closed	-$70K	–	2007
2021 Q1	$70K	Buy	+183	New	+$79.9K	0.01%	1388
2020 Q3	–	Sell	-114	Closed	-$260K	–	1454
2020 Q2	$260K	Buy	+114	New	+$184K	0.03%	617

Other funds holding SCNI

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial's SCNI Position: Q1 2026 in Review

Virtu Financial sold out of Scinai Immunotherapeutics (SCNI) in Q1 2026, closing a stake of 15,409 shares — an estimated $11K sold.

Virtu Financial first reported a position in SCNI in Q2 2020 and held it in 5 quarters. The position peaked at $260K in Q2 2020. 4 funds tracked by Wall St. Rank hold SCNI as of Q1 2026.

Virtu Financial reported no remaining Scinai Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
Virtu Financial sold 15,409 Scinai Immunotherapeutics shares in Q1 2026, an estimated $11K.
Virtu Financial first reported a position in Scinai Immunotherapeutics in Q2 2020 and held it in 5 quarters.
Virtu Financial's Scinai Immunotherapeutics position peaked at $260K in Q2 2020.
4 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.